Pushkar DY, et al. - In this randomized, open-label, tolterodine-controlled, comparative multicenter trial, authors studied 300 candidates to assess the safety and efficiency of imidafenacin 0.2 mg in comparison to tolterodine 4 mg per day in subjects with overactive bladder (OAB). They recorded the change in the mean number of incontinence episodes, −2.1 ± 2.2 in the imidafenacin group vs −1.9 ± 1.8 in the tolterodine group after treatment. They also noted the change in the mean number of daytime incontinence episodes, −1.7 ± 1.7 and −1.5 ± 1.4. Reduction in the OAB Awareness Tool score by 14.2 ± 8.5 and 14.5 ± 8.0, respectively were also observed. They also reported the resolution of most adverse events (mild in nature) without treatment. They overall concluded imidafenacin and tolterodine noninferior in the treatment of Caucasian cases with OAB.